Notitia Biologics

Notitia Biotechnologies is a private, microbiome-focused biotechnology company developing therapeutics, nutrition products, and data-driven diagnostics centered on restoration of a healthy gut ecosystem. The company's core concept is the "Foundation Guild," a proprietary framework describing beneficial gut microbial communities that support metabolic and immune health. Notitia has advanced NBT-NM108, a fiber-based microbiome-modulating product with FDA IND status, into Phase 2 development in COVID-19 and has also described programs in diabetic kidney disease and other microbiome-linked conditions. In parallel, the company markets wellness products such as Guild:Plus and positions its science around microbiome analysis, ecological restoration, and personalized healthspan improvement. The business appears to remain private and early stage, with limited publicly disclosed financing and a small operational footprint in New Jersey.